Celularity Inc

Name: Celularity Inc standardized financial statements, quarterly
Creator: Listed

CELUNasdaqCIK 1752828HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$5.4m, Q2 FY2026

Operating income−$4.2m, Q2 FY2026

Net income$706.0k, Q2 FY2026

Celularity Inc, income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	3.8	12.1	14.7	12.1	9.3	18.1	11.4	5.7	5.3	4.1	3.8	5.4
Cost of revenue	$m	3.6	9.6	1.6	2.1	3.9	7.3	3.6	5.2	3.9	7.4	1.5	2.3
Gross profit	$m	0.2	2.5	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Research and development	$m	5.2	(0.3)	5.8	3.8	3.9	3.8	3.7	3.4	4.6	3.3	3.0	2.0
Selling, general and administrative	$m	10.7	13.1	14.0	15.9	12.7	16.1	14.3	12.6	9.3	15.1	9.2	4.9
Operating income	$m	(99.3)	13.3	(7.4)	(10.2)	(11.5)	(9.3)	(10.5)	(15.9)	(12.9)	(22.1)	(10.1)	(4.2)
Interest expense	$m	not reported	not reported	not reported	not reported	not reported	not reported	2.4	1.9	not reported	not reported	0.4	0.2
Income tax	$m	0.0	0.0	0.0	0.0	0.0	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Net income	$m	(93.9)	9.5	(22.0)	(6.5)	(16.1)	(13.3)	(19.8)	(24.5)	(23.1)	(24.4)	0.9	0.7
Diluted EPS	$ per share	(4.98)	not reported	(1.03)	(0.30)	(0.73)	not reported	(0.84)	(1.02)	(0.88)	not reported	0.02	0.02
Basic EPS	$ per share	(4.98)	not reported	(1.03)	(0.30)	(0.73)	not reported	(0.84)	(1.02)	(0.88)	not reported	0.02	0.02

Balance sheet

Cash and equivalents$586.0k, Q2 FY2026

Shareholders' equity−$35.5m, Q2 FY2026

Celularity Inc, balance sheet, quarterly
Line item	Unit	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	period not labelled2024-07-29	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	0.2	1.9	0.5	not reported	0.1	0.7	0.3	0.9	0.1	6.2	0.4	0.6
Current assets	$m	19.8	22.9	17.7	not reported	14.5	20.6	22.1	17.3	10.6	12.3	6.3	6.4
Total assets	$m	144	144	135	not reported	129	133	129	120	114	107	99.5	96.2
Current liabilities	$m	67.3	66.0	67.9	not reported	76.2	53.7	58.7	69.2	65.3	80.8	70.6	59.7
Total liabilities	$m	103	113	108	not reported	112	124	134	146	134	145	135	132
Long-term debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Current portion of debt	$m	39.2	39.8	41.0	42.7	42.6	not reported	6.3	6.3	not reported	not reported	not reported	not reported
Short-term borrowings	$m	17.2	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	41.0	31.2	27.8	not reported	17.3	8.8	(5.5)	(25.5)	(20.1)	(38.1)	(35.3)	(35.5)

Cash flow

Operating cash flow−$1.1m, Q2 FY2026

Capital expenditure$91.0k, Q4 FY2024

Celularity Inc, cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(8,322)	(4,341)	(4,403)	(3,448)	(144)	1,594	(2,993)	(999)	(4,159)	(5,103)	1,447	(1,108)
Capital expenditure	$k	228	580	39.0	31.0	0.0	91.0	not reported	not reported	not reported	not reported	not reported	not reported
Share repurchases	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)29.34m, Q2 FY2026

Celularity Inc, shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	151	15.5	17.7	18.8	21.4	21.8	22.0	23.5	24.0	26.3	30.3	29.3

Shares outstanding: 32.45m at Oct 19, 2026, from the cover of the 10-Q filed Oct 20, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. Listed shows no prices and gives no investment advice.